Clinical Trials
9
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
A Multicenter Clinical Trial of Ingaron in Pulmonary Tuberculosis
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- SPP Pharmaclon Ltd.
- Target Recruit Count
- 350
- Registration Number
- NCT06118619
- Locations
- 🇷🇺
Astrakhan Oblast Tuberculosis Clinic, Astrakhan, Astrakhan Oblast, Russian Federation
🇷🇺Tuberculosis Clinic of the Chuvash Republic, Cheboksary, Chuvash Republic, Russian Federation
🇷🇺Leningrad Oblast Tuberculosis Clinic, Slantsy, Leningrad Oblast, Russian Federation
Study of Ingaron's Effect on Efficacy and Resistance to Antibiotics in Community-acquired Pneumonia
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- SPP Pharmaclon Ltd.
- Target Recruit Count
- 114
- Registration Number
- NCT05395702
- Locations
- 🇷🇺
City Clinical Hospital named after M.E. Zhadkevich Moscow City Health Department, Moscow, Russian Federation
Study of the Use of the Drug Ingaron in Patients With COVID-19
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- SPP Pharmaclon Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT05386459
- Locations
- 🇷🇺
City Clinical Hospital named after M.E. Zhadkevich Moscow City Health Department, Moscow, Russian Federation
Study of the Use of the Ingaron in Volunteers for the Prevention of COVID-19
- Conditions
- COVID-19 Respiratory Infection
- Interventions
- Drug: Interferon gamma human recombinant (IFN-G)
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2022-05-23
- Lead Sponsor
- SPP Pharmaclon Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT05386446
- Locations
- 🇷🇺
City Clinical Hospital named after M.E. Zhadkevich Moscow City Health Department, Moscow, Russian Federation
Efficiency and Safety of the Drug Ingaron (Interferon-gamma Human Recombinant) in the Treatment of Chronic Prostatitis
- Conditions
- Chronic Prostatitis
- Interventions
- Drug: Interferon gamma human recombinant (IFN-G)
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- SPP Pharmaclon Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05378646
- Prev
- 1
- 2
- Next